| Acamprosate, Criteria for Non-Formulary Use |
| Agalsidase, Criteria for Non-Formulary Use |
| Alemtuzumab, Criteria For Non-Formulary Use |
| Aliskiren, Criteria For Non-Formulary Use |
| Alpha-Adrenergic Blockers in the Management of Patients with HTN (ALLHAT) |
| Antiviral Agents for Influenza, Criteria For Use |
| Azacitidine, Criteria for Use |
| Topical Anesthesia for Surfaces of the Nasopharynx, Oropharynx, Laryngotracheal Region and Airway, Criteria for Use |
| Clinically Uroselective Alpha Adrenergic Blockers, Criteria for Non-Formulary Use |
| Combination Alpha-Blocker & Finasteride Therapy for BPH, Criteria for Use |
| Consensus Interferon, Criteria for use in Hepatitis C, Criteria for Use |
| Angiotensin II Receptor Antagonists (AIIRAs), Criteria for Use |
| Antiemetic, Criteria for Use |
| Atazanavir, Criteria for Use |
| Becaplermin, Criteria for Non-Formulary Use |
| Beta-Adrenergic Blockers (Heart Failure), Clinical Recommendations |
| Biologics for Psoriasis, Criteria for Non-Formulary Use (Updated) |
| Buprenorphine, Criteria for Use |
| Cholinesterase Inhibitor, Criteria for Use |
| Cilostazol, Criteria for Use |
| Cinacalcet, Criteria for Non-Formulary Use |
| Clopidogrel, Criteria for Use |
| Darunavir, Criteria for Use |
| Dihydropyridine (Long-Acting) Calcium Channel Blockers, Clinical Guidance |
| Drotrecogin Alfa, Criteria for Use |
| Drotrecogin Alfa Checklist |
| Duloxetine, Criteria for Non-Formulary Use |
| Enfuvirtide,, Criteria for Use |
| Enoxaparin, Criteria for Use in Mechanical Heart Valve Patients |
| Erlotinib, Criteria for Non-Formulary Use |
| Erythropoietin Criteria for Use for Hepatitis C,, Criteria for Use |
| Eszopiclone, Criteria for Non-Formulary Use |
| Etravirine, Criteria for Use |
| Exenatide, Criteria for Non-Formulary Use |
| Ezetimibe or Ezetimibe+Simvastatin Criteria for Non-Formulary Use |
| Fondaparinux (Currently Under Revision), Criteria for Use |
| Fluoroquinolone, Criteria for Use |
| Fluvastatin, Pravastatin, Atorvastatin, Rosuvastatin Criteria |
| Fuzeon Criteria for Use |
| Gabapentin, Criteria for Use |
| Gefitinib Criteria for Non-Formulary Use |
| GSCF Criteria for Use for Hepatitis C Criteria for Use |
| HMGs, Criteria for Non-Formulary Use in Patients Receiving Protease Inhibitor Therapy |
| Highly Teratogenic Retinoids and High-dose Vitamin A, Criteria for use |
| Imatinib, Criteria for use |
| Initiating Therapy In Early Parkinson’s Disease, Criteria for use |
| Imiquimod, Criteria for Use |
| Leflunomide and Biologic DMARDs for Rheumatoid Arthritis, Criteria for use |
| Leukotriene Inhibitor, Criteria for Use |
| Leuprolide Implantable (Viadur) Criteria for Non-Formulary Use |
| Levetiracetam, Criteria for Use |
| Linezolid, Quinupristin-Dalfopristin, and Daptomycin,, Criteria for Use |
| Lovaza (formerly Omacor),, Criteria for Use |
| Lubiprostone Criteria for Non-Formulary Use |
| Maraviroc, Criteria for Use (Check-Box Format) |
| Memantine, Criteria for Use |
| Meperidine, Criteria for Use |
| Monoamine Oxidase Inhibitors (MAOI), Criteria for Use |
| Moxifloxacin Ophthalmic Solution, Criteria for Use |
| Naltrexone Extended-release Injectable Suspension Criteria for Non-formulary Use |
| Novoseven Monograph |
| Omalizumab, Criteria for Non-formulary Use |
| Orlistat - Criteria for Use |
| Oxycodone CR, Criteria for use, Treatment Algorithm |
| Oxymorphone Oral Tablets - Criteria for Use |
| Pantoprazole I.V. Criteria for Use Pantoprazole I.V. Literature Review |
| Pegaptanib, Criteria for Non-Formulary Use |
| Pegfilgrastim, Criteria for Non-Formulary Use |
| Pemetrexed, Criteria for Non-Formulary Use |
| Pharmacologic Management of Primary Pulmonary Hypertension, Criteria for Use |
| Phosphate Binder, Criteria for Use |
| Pramlintide, Criteria for Non-Formulary Use |
| Pregabalin, Criteria for Non-Formulary Use |
| Propoxyphene, Criteria for Use |
| Proton Pump Inhibitors, High-dose,Criteria for Use |
| Appendix I(Nocturnal Leg Cramps) |
| Quadrivalent HPV Vaccine (Gardasil), Criteria for Non-Formulary Use |
| Raltegravir, Criteria for Use |
| Ramipril, Criteria for Non-Formulary Use |
| Ranolazine, Criteria for Non-Formulary Use |
| Rifaximin, Criteria for Non-Formulary Use |
| Rifaximin, Criteria for Non-Formulary Use (Check-box format) |
| Risperidone Long-Acting, Criteria for Use |
| Rituximab, Criteria for Use |
| Sibutramine - Criteria for Use |
| Sitagliptin, Criteria for Non-Formulary Use |
| Synvisc and Hyalgan, Criteria for Non-Formulary Use |
| Teriparatide, Criteria for Non-Formulary Use |
| Thickening Agents for Outpatients, Criteria for Use |
|
Tiotropium, Criteria for Use |
| Tipranavir, Criteria for Use |
|
Thiazolidinedione , Criteria for Non-Formulary Use |
| Vardenafil Non-Responders, Criteria for Non-Formulary Use |
| Ziconotide, Criteria for Non-Formulary Use & Ziconotide, Monograph |
| Ziprasidone IM, Criteria for Non-Formulary Use |
| Ziprasidone, Criteria for Use |
| Zoster Vaccine, Criteria for Use |
